N-acetylcysteine (NAC) is a glutathione precursor that the body can use to produce glutathione naturally and has better absorption than oral glutathione
This makes semaglutide a valuable option for individuals with type 2 diabetes who are at an increased risk of cardiovascular complications
References: Beutler E, Felitti VJ, Gelbart T, Ho N
Atherosclerotic cardiovascular disease beginning in childhood
Market Opportunities Biosimilar Liraglutide Access Markets, Emerging Geography Expansion, and Precision Obesity Medicine Unlock Underserved GLP-1 Market Growth Segments Biosimilar liraglutide entry represents the first generic competition wave for the GLP-1 weight loss drug category, expanding access for the 480 million obesity patients in lower-middle income countries for whom USD 1,000-plus monthly branded drug pricing is permanently inaccessible
Allow 2-3 minutes for absorption